AI assistant
IMUGENE LIMITED — Share Issue/Capital Change 2020
Nov 1, 2020
65124_rns_2020-11-01_2e573816-4ba8-4e62-a2e4-a060047102e4.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [116 x 42] intentionally omitted <==
ASX Announcement
Letter to IMUOA Optionholders
Sydney, Australia, 2 November 2020 : Imugene Limited (ASX: IMU or the Company ), a clinical stage immuno-oncology company advises that the attached notice of expiry of IMUOA options letter was sent to all holders of IMUOA listed options (Options) which are exercisable at $0.026 each on or before 5:00pm AEDT on Monday, 30 November 2020 (Expiry Date).
Official quotation of the Options will cease at close of trading on 24 November 2020, being four business days before the Expiry Date.
Holders of the Options can exercise all or part of their Options prior to the Expiry Date. Please find enclosed the sample “notice of exercise of options” for further instructions.
-End-
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Managing Director and Chief Executive Officer
IMUGENE LIMITED Level 3, 62 Lygon Street, Carlton, VIC, 3053, AUSTRALIA
==> picture [42 x 43] intentionally omitted <==
30 October 2020
Dear Option Holder,
Notice of Expiry of IMUOA Options
We want to thank you for your continued support.
The 30 November 2020 expiry date for IMUOA listed options is approaching and the Company would like to remind option holders that the IMUOA options NOT exercised by 30 November 2020 will automatically lapse.
Please find below information required to be provided to you in accordance with the ASX Listing Rules.
| Please find below information required to be provided to | you in accordance with the ASX Listing Rules. |
|---|---|
| Number of shares to be issued on exercise of options | One fully paid ordinary share (ASX: IMU) per option that is exercised |
| Exercise price | $0.026 per option |
| Due date for payment | 30 November 2020 |
| Consequence of non-payment | Options will lapse |
| Date quotation of IMUOA on ASX will end | 24 November 2020 (at end of trade) |
| Latest market price for IMU | $0.056 (27 October 2020) |
| 3 Month IMU low price | $0.045 (11 September 2020) |
| 3 Month IMU high price | $0.065 (27 July 2020) |
| Underwriting | The Company has entered into an underwriting agreement detailed in the ASX announcement on 9 September 2020. |
If you wish to exercise your options, you may do so in whole or in part.
Your enclosed option exercise form includes both your personalised BPAY and Electronic Funds Transfer (EFT) payment details.
The total exercise price for the options which you chose to exercise (if any) can be paid by BPAY or EFT, and the completed option exercise form (where applicable if opting NOT to exercise in full) must be returned to our Share Registry by email to [email protected].
For further instructions please see enclosed option exercise form.
If the options exercise form (where applicable if opting NOT to exercise in full), together with cleared funds, is not received by our share registry on or before the expiry date (Monday, 30 November 2020), then your IMUOA options will expire with no value and no further entitlement will exist.
If you have any queries concerning this Notice or your option holding, please contact the Joint Company Secretary Justyn Stedwell on +61 (0) 3 9824 5254.
Yours faithfully
Leslie Chong CEO/MD Imugene Limited
2
IMUGENE LIMITED
All Registry Communication to:
==> picture [281 x 56] intentionally omitted <==
IMUGENE LIMITED | ACN 009 179 551
[EntityRegistrationDetailsLine1Envelope] [EntityRegistrationDetailsLine2Envelope] [EntityRegistrationDetailsLine3Envelope] [EntityRegistrationDetailsLine4Envelope] [EntityRegistrationDetailsLine5Envelope] [EntityRegistrationDetailsLine6Envelope]
GPO Box 5193, Sydney NSW 2001 1300 288 664 (within Australia) +61 2 9698 5414 (international) [email protected] www.automicgroup.com.au
SRN/HIN: [HolderNumberMasked] Security Code: IMUOA Option Expiry Date: 30 November 2020 Exercise Price: $0.026
NOTICE OF EXERCISE OF OPTIONS
I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. I/We agree to accept such Shares subject to the Constitution of Imugene Limited.
1 EXERCISING ALL YOUR OPTIONS You do not need to return this form if you have chosen to exercise all your current options and made payment via BPAY or EFT. Your unique reference number will process your exercise application electronically.rocess your exercise application electronically.your exercise application electronically.our exercise application electronically.pplication electronically.lication electronically.y.. Number of Options held: Total payment required @ $0.026 per Option exercised [IMUOA] [Payment] 2 EXERCISING YOUR OPTIONS - PARTIAL Please complete this section and return this form to [email protected] if you have chosen to exercise only some of your options and made payment via BPAY or EFT. Number of Options Exercised Payment Amount @ $0.026 per Option exercised A$ , , . , , , Calculate the Payment Amount by multiplying the number of options you wish exercise by A$0.026. If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down. 3 MAKE YOUR PAYMENT BY BPAY® OR ELECTRONIC FUNDS TRANSFER (EFT) Option A – BPAY Option B – Electronic Funds Transfer (EFT) Biller Code: 337006 The unique payment reference number which has been assigned to your Application is: IMUOA[HolderId] Ref No: [BPayCRN] Funds are to be deposited directly to following bank account: ® Registered to BPAY Pty Ltd ABN 69079137518 Account name: Automic Pty Ltd Account BSB: 036011 Contact your financial institution to make your payment from your Account number: 607152 cheque or savings account. You should check the processing cut -off Swift Code: WPACAU2S time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Share Registry IMPORTANT: You must quote your unique reference number as your in time. payment reference/ description when processing your EFT payment. Failure to do so may result in your funds not being allocated to your application and shares subsequently not issued.
You do not need to return this form if you have chosen to exercise all your current options and made payment via BPAY or EFT. Your unique reference number will process your exercise application electronically.rocess your exercise application electronically.your exercise application electronically.our exercise application electronically.pplication electronically.lication electronically.y..
4 CONTACT DETAILS & ELECT TO BE AN E-SHAREHOLDER
As a valued shareholder in Imugene Limited, you can help minimise the costs of printing and mailing by electing to receive all shareholder communications electronically. This will ensure you receive all future important shareholder communications in a faster and more secure way. Please enter your details and return to our Share Registry by email to [email protected] Telephone Number Contact Name (PLEASE PRINT) ( ) Email Address